Business Briefing: Lung Transplant Device Receives Federal Approval
The Food and Drug Administration said Tuesday that the Xvivo Perfusion System could lead to more successful transplants of lungs for people with cystic fibrosis and other deadly respiratory diseases.
Discussion Normal kidneys regulate water balance to maintain a plasma osmolality of 275-290 mOsm/kg normally. Thirst and arginine vasopressin or antidiuretic hormone (ADH) are the primary regulators of plasma osmolality. ADH is made in the hypothalamus and released by the posterior pituitary gland. ADH acts on the kidney’s distal collecting duct to increase water reabsorption. ADH is appropriately released in hypovolemic states, such as dehydration caused by gastroenteritis. ADH has an ~10 minute half-life and therefore can respond to rapid changes in volume status. Sodium balance is regulated by aldosterone (as part...
Publication date: Available online 21 April 2018 Source:Respiratory Physiology & Neurobiology Author(s): Thomas Radtke, Lukas Böni, Peter Bohnacker, Peter Fischer, Christian Benden, Holger Dressel We evaluated test-retest reliability of sputum viscoelastic properties in clinically stable patients with cystic fibrosis (CF). Data from a prospective, randomized crossover study was used to determine within-subject variability of sputum viscoelasticity (G’, storage modulus and G”, loss modulus at 1 and 10 rad s−1) and solids content over three consecutive visits. Precision of sputum properties wa...
Health ministers call on company to lower price of cystic fibrosis drug Orkambi so the NHS can afford it.
Michele Marangi, Giuseppa Pistritto
We report the results of an observational study investigating its effects in CF patients with non-G551D gating mutations.
Antibiotic eradication treatment is the standard-of-care for cystic fibrosis (CF) patients with early Pseudomonas aeruginosa (Pa)-infection; however, evidence from placebo-controlled trials is limited.
Therapies targeting certain CFTR mutants have been approved, yet variations in clinical response highlight the need for in-vitro and genetic tools that predict patient-specific clinical outcomes. Toward this goal, the CF Canada-Sick Kids Program in Individual CF Therapy (CFIT) is generating a “first of its kind”, comprehensive resource containing patient-specific cell cultures and data from 100 CF individuals that will enable modeling of therapeutic responses.
It was back in the 1960s, before computers and the internet, when the power of collecting data on individuals with cystic fibrosis (CF) was first recognized. At that time, CF was almost exclusively a pediatric disease; however, with no national database little was known about the characteristics and survival of those living with the disease. In an effort to better understand the CF population, Dr. Warren Warwick was given a grant to collect statistics from several CF centers in the US. From these data Dr.
A research session co-hosted by the JCF and The Lancet Respiratory Medicine is scheduled for 7th June 2018 at the European Cystic Fibrosis Society conference in Belgrade, Serbia. The session will describe how these journals operate and disseminate the latest findings.
Patients with cystic fibrosis (CF) who experience acute declines in percent predicted FEV1 (ppFEV1 decreased ≥10% relative to baseline) are often not treated with antibiotics for pulmonary exacerbations (PEx), whereas other patients are treated even when they have not experienced a decline in lung function.